Journal of Modern OncologyJournal of Modern Oncology1815-14341815-1442LLC Obyedinennaya Redaktsiya26940Short CommunicationPress Release. New data show Giotrif® (afatinib) provided more than one year additional survival for patients with lung cancer associated with the most common type of EGFR mutation (del19) compared to chemotherapy---1509201416309042020Copyright © 2014, Consilium Medicum2014[Yang J, Sequist L et al. Overall survival (OS): In patients with advanced non - small cell lung cancer (NSCLC) harbouring common (Del19/L858R) Epidermal Growth Factor Receptor mutations (EGFR mut): pooled analysis of two large open - label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6] comparing afatinib with chemotherapy. Abstr. 8004 presented at 2014 American Society of Clinical Oncology, 50th Annual Meeting, 30 May-3 June 2014, Chicago, IL, USA.][Quest Diagnostics - Lung Cancer Mutation Panel. http://www.questdi-agnostics.com/hcp/intguide/jsp/showintguidepage.jsp?fn=TS_Lung - CancerMutation_Panel.htm][Yang J et al. J Clin Oncol 2013; 31: 3342-50. http://jco.ascopubs.org/content/31/27/3342.full][Wu Y-L et al. Lancet Oncol 2014; 15: 213-22. http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70604-1/fulltext]